Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Sciwind Biosciences Co. Ltd.
BioCentury | Mar 26, 2025
Data Byte
China deals look beyond cancer
At least eight East-to-West licensing deals outside oncology so far this year
BioCentury | Mar 15, 2025
Editor's Commentary
The NewCo model spurs debate, but it’s about more than money — a Perspective
Expanding the dealmaker’s toolkit to bring Asian innovation to the West
BioCentury | Mar 12, 2025
Deals
Building biotech ecosystems in Asia: an East-West Summit podcast
Takeaways from BioCentury’s East-West Biopharma Summit focus on Japan, India, China, plus the NewCo Model
BioCentury | Mar 7, 2025
Product Development
Could amylin outshine GLP-1 in obesity?
If the preclinical data translate to the clinic, amylin has a good chance to supplant GLP-1 for the overweight to moderate obesity population
BioCentury | Mar 3, 2025
Deals
The dealmaking at the heart of the NewCo boom
Formed with Hummingbird assets, $187M, Callio brings trend to Singapore
BioCentury | Feb 6, 2025
Management Tracks
Arcturus appoints Slaoui chair designate
Plus: Affinia hires Makimura and Xu joins Sciwind
BioCentury | Jan 29, 2025
Deals
The NewCo boom signals China’s galloping speed of innovation
Companies founded in the West with Asian assets tell a story of China speed
BioCentury | Jan 11, 2025
Finance
Pre-JPM venture bonanza
Fourteen companies announce series A rounds ahead of conference, six with over $100 million
BioCentury | Sep 10, 2024
Product Development
More contenders enter oral obesity race
But efficacy for oral GLP-1 agonist TERN-601, ecnoglutide still falls short of Roche, Novo
BioCentury | May 14, 2024
Deals
Deals Report: Sanofi-Novavax to co-commercialize Nuvaxovid, develop combination vaccines
Plus: Maze finds Pompe disease program partner in Shionogi, and updates from Takeda-AC Immune, Sanofi-Fulcrum and more
Items per page:
1 - 10 of 15